Volume | 1,400,065 |
|
|||||
News | - | ||||||
Day High | 25.4699 | Low High |
|||||
Day Low | 23.44 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Beam Therapeutics Inc | BEAM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
24.04 | 23.44 | 25.4699 | 23.47 | 24.10 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,890 | 1,400,065 | $ 24.37 | $ 34,115,676 | - | 16.95 - 49.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:18:44 | 1 | $ 24.50 | USD |
Beam Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.92B | 81.66M | - | 377.71M | -132.53M | -1.62 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Beam Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BEAM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 25.23 | 26.14 | 23.205 | 24.31 | 2,360,988 | -1.18 | -4.68% |
1 Month | 34.31 | 34.6759 | 23.205 | 27.15 | 1,610,329 | -10.26 | -29.90% |
3 Months | 28.00 | 49.50 | 23.205 | 32.36 | 1,541,603 | -3.95 | -14.11% |
6 Months | 17.45 | 49.50 | 16.95 | 28.87 | 1,503,344 | 6.60 | 37.82% |
1 Year | 31.16 | 49.50 | 16.95 | 28.66 | 1,182,819 | -7.11 | -22.82% |
3 Years | 74.84 | 138.5219 | 16.95 | 47.70 | 1,019,223 | -50.79 | -67.86% |
5 Years | 19.19 | 138.5219 | 13.00 | 50.08 | 914,084 | 4.86 | 25.33% |
Beam Therapeutics Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. |